1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Age-Related Vision Dysfunction - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2024-2034)
4.4 Market Overview (2019-2024) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Age-Related Vision Dysfunction - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Age-Related Vision Dysfunction - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Age-Related Vision Dysfunction - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Age-Related Vision Dysfunction - Unmet Needs
10 Age-Related Vision Dysfunction - Key Endpoints of Treatment
11 Age-Related Vision Dysfunction - Marketed Products
11.1 List of Age-Related Vision Dysfunction Marketed Drugs Across the Top 7 Markets
11.1.1 Vuity (Pilocarpine Hydrochloride Ophthalmic Solution) - Allergan
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Lucentis (Ranibizumab Injection) - Genentech/Novartis Ophthalmics
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vabysmo (Faricimab-Svoa) - Genentech
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Macugen (Pegaptanib Sodium Injection) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Beovu (Brolucizumab) - Novartis
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Age-Related Vision Dysfunction - Pipeline Drugs
12.1 List of Age-Related Vision Dysfunction Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Age-Related Vision Dysfunction - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Age-Related Vision Dysfunction – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Age-Related Vision Dysfunction - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Age-Related Vision Dysfunction - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Age-Related Vision Dysfunction - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Age-Related Vision Dysfunction - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Age-Related Vision Dysfunction - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Age-Related Vision Dysfunction - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Age-Related Vision Dysfunction - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Age-Related Vision Dysfunction - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Age-Related Vision Dysfunction - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Age-Related Vision Dysfunction - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
16 Age-Related Vision Dysfunction - Recent Events and Inputs From Key Opinion Leaders
17 Age-Related Vision Dysfunction Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Age-Related Vision Dysfunction Market – Strategic Recommendations
19 Appendix